The Circulating Cell-free Genome Atlas Study

Overview

Información sobre este estudio

GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

Non-Cancer Arm Subjects

  • Age 20 years or older.
  • Able to provide a written informed consent.

Inclusion Criteria for Cancer Arm Subjects

  • Age 20 years or older.
  • Able to provide a written informed consent.
  • Have either of the following:
    • Confirmed cancer diagnosis (any stage I-IV, as well as carcinoma in situ (CIS)) within 90 days prior to or up to 42 days after study blood draw, based upon assessment of a pathological specimen (including, but not limited to, biopsy from primary tumor site, lymph node or metastatic lesion, or cytology specimen, or bone marrow or blood specimen for hematological malignancies); or
    • A high suspicion for a cancer diagnosis by clinical and/or radiological assessment, with planned biopsy or surgical resection to establish a definitive diagnosis within 6 weeks (42 days) after study blood draw

Exclusion Criteria:

Non-Cancer Arm Subjects

  • Known current or prior diagnosis of cancer except non-melanoma skin cancer.
    • Exception: subjects with history of non-melanoma skin cancer; e.g., BCC or SCC that has been effectively and exclusively managed by local or focal therapies such as surgical resection, radiation therapy, cryotherapy or topical therapy, are eligible to enroll.
  • Oral or IV corticosteroid use in past 14 days prior to blood draw.
  • Pregnancy (by self-reporth of pregnancy status).
  • Current febrile illness.
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
  • Poor health status or unfit to tolerate blood draw.

Cancer Arm Subjects

  • Known prior diagnosis of cancer separate from the confirmed or suspected cancer diagnosis associated with study enrollment.
    • Exception: subjects with history of non-melanoma skin cancer; e.g,. BCC or SCC that has been effectively and exclusively managed by local or focal therapies such as surgical resection, radiation therapy, cryotherapy or topical therapy, are eligible to enroll.
  • Currently receiving, or ever received, any of the following therapies to treat their current cancer: surgical management of the cancer beyond that required to establish the cancer diagnosis; local, regional or systemic chemotherapy including chemoembolization; targeted therapy, immunotherapy including cancer vaccines; hormone therapy; or radiation therapy.
  • Pregnancy (by self-report of pregnancy status).
  • Current febrile illness.
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
  • Poor health status or unfit to tolerate blood draw.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Lisa Boardman, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Investigador principal de Mayo Clinic

David Thiel, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Niloy Jewel Samadder, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20303079

Mayo Clinic Footer